Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer

National Institutes of Health Clinical Center (CC)

Status and phase: Completed; Phase 1

Conditions: Pancreatic Cancer

Treatments: Other: pharmacological study; Other: high performance liquid chromatography; Radiation: [18F]-labeled substance P antagonist receptor quantifier

Study type: Interventional

Funder types: NIH

Identifiers

NCT00547612

07-C-0222

CDR0000570181

070222

Details and patient eligibility

About

RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using [18F]-labeled substance P antagonist receptor quantifier, may be effective in finding disease in patients with pancreatic cancer.

PURPOSE: This phase I trial is studying how well a PET scan using [18F]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.

Full description

OBJECTIVES:

• Determine whether [18F]-labeled substance P antagonist receptor quantifier positron emission tomography can identify pancreatic cancer evident on multiphase CT scan.

OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than 15 days later, patients receive [18F]-labeled substance P antagonist receptor quantifier IV and undergo positron emission tomography over 6 hours.

Blood is collected periodically to measure the metabolism of the radiotracer by high performance liquid chromatography with radioactive detectors.

Enrollment: 33 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed adenocarcinoma of the pancreas

  • Primary or metastatic disease

• At least one site of measurable disease

• Enrolled in an NCI protocol (either a treatment or screening protocol) such as NCI-05-C-0044 or NCI-05-C-0141

PATIENT CHARACTERISTICS:

Inclusion criteria:

• ECOG performance status 0-2
• WBC ≥ 1,200/mm³
• Creatinine < 2.0 mg/dL
• Negative pregnancy test
• Fertile patients must agree to use effective contraception
• Not pregnant or nursing

Exclusion criteria:

• Allergy to IV contrast
• Claustrophobia that would preclude completion of a scan or unable to lie on one's back for positron emission tomography scan

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

• More than 4 weeks since prior abdominal surgery

Exclusion criteria:

• Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits
• Aprepitant within 72 hours of [18F]-labeled substance P antagonist receptor quantifier positron emission tomography